Coagulation Analyzer Market Report 2025

The coagulation analyzer market size has grown strongly in recent years. It will grow from $3.09 billion in 2024 to $3.29 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to increasing aging population, rise in chronic diseases, growing surgical procedures, anticoagulant therapy monitoring, rising incidence of hemophilia.

The coagulation analyzer market size is expected to see strong growth in the next few years. It will grow to $4.58 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to point-of-care testing (POCT) adoption, rising demand for home-based monitoring, integration of connectivity solutions, increasing focus on personalized medicine, global expansion of hemostasis management programs. Major trends in the forecast period include technological innovations in assay design, advancements in technology, miniaturization and portability, multiplex assays for comprehensive testing, collaborations for research and development.

The anticipated increase in the prevalence of leukemia is set to drive the growth of the coagulation analyzer market. Leukemia, a form of blood cancer characterized by the rapid proliferation of abnormal blood cells, impacts the body's ability to combat infections, affecting the lymphatic system and bone marrow. Coagulation analyzers play a crucial role in assisting leukemia patients by testing for disseminated intravascular coagulation (DIC), evaluating factors such as prolonged PT, low fibrinogen levels, platelet counts, and elevated D-dimer levels. Notably, in January 2023, the American Cancer Society reported a total of 59,610 new cases of leukemia and 23,710 leukemia-related deaths. Additionally, GLOBOCAN, an online cancer statistics database, indicated 474,519 new cases of leukemia globally in 2020. This surge in leukemia cases underscores the significant contribution to the growth of the coagulation analyzer market.

The rising incidence of cardiac diseases is expected to drive the growth of the coagulation analyzer market in the coming years. Cardiac diseases include a variety of conditions that affect both the heart and blood vessels. Coagulation analyzers are utilized in the management of cardiac diseases by assessing blood clotting parameters, guiding anticoagulant therapy, and preventing complications, thereby contributing to effective treatment and care. For example, in August 2022, a report from the American College of Cardiology, a US-based non-profit medical association, projected that all four cardiovascular risk factors in the United States would increase between 2025 and 2060. The most significant rise is expected in diabetes, with a 39.3% increase to 55 million individuals, followed by dyslipidemia (up 27.6% to 126 million), hypertension (up 25.1% to 162 million), and obesity (up 18.3% to 126 million). The researchers also noted that the most substantial projected increases in cardiovascular disease rates would be for stroke (up 33.8% to 15 million) and heart failure (up 33.4% to 13 million), followed by ischemic heart disease (up 30.7% to 29 million) and heart attack (up 16.9% to 16 million). Therefore, the rising incidence of cardiac diseases is driving the growth of the coagulation analyzer market.

A prominent trend in the coagulation analyzer market is the increasing focus on product innovations, with major companies actively developing advanced solutions to maintain their market positions. An illustrative example is Charles River Laboratories International, Inc., a US-based non-clinical contract research organization, which introduced the Endosafe Nexus 200 in December 2022. Positioned as a valuable addition to its comprehensive endotoxin testing line, the Nexus 200 is a fully robotic instrument known for its data integrity compliance. Utilizing Endosafe Limulus Amebocyte Lysate (LAL) cartridge technology, the Nexus 200 is designed for handling simple or complex serial dilutions for water, in-process, and final product testing. Equipped with Endosafe EndoScan-V version 6.1, the system enables data exportation into a Laboratory Information Management System (LIMS) interface, providing enhanced traceability, security, and integrated touch screen data management.

Major companies in the coagulation analyzer market are developing technologically advanced products, such as fully automated coagulation analyzers, to manage high test volumes with minimal human intervention. A fully automated coagulation analyzer is a laboratory device that performs automated testing of blood clotting processes, enabling accurate and efficient diagnosis of coagulation disorders without the need for manual input. For example, in March 2024, Zybio Inc., a China-based provider of in vitro diagnostic reagents and equipment, launched the EXT 9800 fully automated coagulation analyzer. The EXT 9800 is notable for being the first to employ micro magnetic particle detection, allowing for visualized, multi-dimensional analysis of the coagulation process, which enhances accuracy and depth. It redefines automated detection with a distributed structure, modular expandability, and high-throughput capabilities, offering a lightweight, comprehensive solution for laboratories. Additionally, the analyzer features a complete upgrade across the entire testing process, establishing a new standard for innovation in coagulation testing.

In December 2023, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., a medical device company based in China, acquired a 75% stake in DiaSys Diagnostic Systems GmbH for an undisclosed amount. This acquisition will enable Mindray to accelerate the development of its overseas supply chain platform, access a skilled international team, and enhance its in-vitro diagnostics portfolio. Mindray is committed to providing resources and support to DiaSys while leveraging its extensive experience in global integration to promote effective synergistic growth for both companies. DiaSys Diagnostic Systems GmbH is a manufacturer of coagulation analyzers based in Germany.

Major companies operating in the coagulation analyzer market include Siemens AG, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Medtronic plc, Beckman Coulter Inc., Sysmex Corporation, Werfen S.A., Nihon Kohden Corporation, Instrumentation Laboratory Company, ARKRAY Inc., Maccura Biotechnology Co. Ltd., Beijing Succeeder Technology Inc., Helena Laboratories Corporation, Diagnostica Stago Sas, Trivitron Healthcare Pvt. Ltd., A&T corporation, ACON Laboratories Inc., Genrui Biotech Inc., Teco Medical Instruments, Eurolyser Diagnostica GmbH, Bio Group Medical System, LAbor BioMedical Technologies GmbH, Alere Inc., AGD Biomedicals Pvt Ltd, VSI Electronics Private Limited, Micro Lab Instruments, Meril Life Science Pvt. Ltd., Jinan Kinghawk Technology Co. Ltd, Bioevopeak Co. Ltd.

North America was the largest region in the coagulation analyzer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the coagulation analyzer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the coagulation analyzer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A coagulation analyzer is a medical device designed to swiftly and efficiently measure blood platelet levels. Its primary function involves assessing the blood's clotting ability, enabling the identification and evaluation of bleeding disorders such as hemophilia. Additionally, it aids in monitoring patients who are prescribed anticoagulant medications such as aspirin, heparin, or warfarin.

The principal product categories of coagulation analyzers comprise semi-automated coagulation analyzers, automated coagulation analyzers, manual analyzers, and other specialized variants. Semi-automated coagulation analyzers serve as essential medical diagnostic tools for assessing various components present in human blood. These analyzers facilitate multiple test types, including prothrombin time testing, fibrinogen testing, activated partial thromboplastin time testing, d-dimer testing, platelet function testing, anti-factor Xa testing, among others. These tests utilize diverse technologies such as optical, mechanical, electrochemical, and other advanced methodologies. Coagulation analyzers cater to a range of end-users, including hospitals, clinics, diagnostic centers, and other medical facilities where the accurate assessment of blood coagulation is crucial for diagnosis and treatment purposes.

The coagulation analyzer market research report is one of a series of new reports that provides coagulation analyzer market statistics, including coagulation analyzer industry global market size, regional shares, competitors with a coagulation analyzer market share, detailed coagulation analyzer market segments, market trends, and opportunities, and any further data you may need to thrive in the coagulation analyzer industry. This coagulation analyzer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The coagulation analyzer market consists of sales of hematology coagulation analyzers, standalone coagulation analyzers, and portable analyzers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.